Olopatadine/mometasone

Olopatadine/mometasone
Combination of
OlopatadineSelective histamine H1-receptor antagonist
MometasoneTopical corticosteroid
Clinical data
Trade namesRyaltris
Other namesGSP 301
License data
Pregnancy
category
Routes of
administration		Nasal spray
ATC code
  • None
Legal status
Legal status

Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older.[1][2][3] It contains olopatadine hydrochloride and mometasone furoate monohydrate.[1][2] It is sprayed into the nose.[1][2]

Common side effects include an unpleasant taste (dysgeusia).[1]

It was approved for medical use in Australia in December 2019,[1][4] and in the United States in January 2022.[2]

References

  1. 1 2 3 4 5 6 7 "Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate) Nasal Spray". Retrieved 25 July 2020.
  2. 1 2 3 4 5 Hikma Specialty USA Inc. (January 2022). "Highlights of Prescribing Information: RYALTRIS (olopatadine hydrochloride and mometasone furoate monohydrate nasal spray)" (PDF). U.S. Food and Drug Administration.
  3. ↑ Chen R, Zheng D, Zhang Y, Sima G (September 2021). "Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis". European Archives of Oto-rhino-laryngology. doi:10.1007/s00405-021-07085-w. PMID 34591150. S2CID 238223252.
  4. ↑ "Ryaltris nasal spray approved in Australia". OINDPnews. 20 December 2019. Retrieved 25 July 2020.
  • "Olopatadine". Drug Information Portal. U.S. National Library of Medicine.
  • "Mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02631551 for "Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-301)" at ClinicalTrials.gov
  • Clinical trial number NCT02870205 for "Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-304)" at ClinicalTrials.gov


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.